Table S2.
Reported adverse events during 4-wk treatment assessed using the DOTES
| Adverse event | OXT (%), n = 14 | Placebo (%), n = 18 |
| General | ||
| Cold symptoms | 0 (0) | 1 (6) |
| Fever | 0 (0) | 1 (6) |
| Cough | 1 (7) | 0 (0) |
| Neurological/psychiatric | ||
| Headache | 1 (7) | 0 (0) |
| Insomnia | 1 (7) | 1 (6) |
| Excitement/agitation | 1 (7) | 2 (11) |
| Depressive affect | 0 (0) | 1 (6) |
| Labile mood | 1 (7) | 1 (6) |
| Silly behavior | 1 (7) | 0 (0) |
| More distractible | 1 (7) | 0 (0) |
| HEENT | ||
| Nasal congestion | 3 (21) | 0 (0) |
| Epistaxis | 1 (7) | 0 (0) |
| Sneezing | 0 (0) | 1 (6) |
| Mouth pain | 0 (0) | 1 (6) |
| Intranasal swelling | 1 (7) | 0 (0) |
| Runny nose | 1 (7) | 0 (0) |
| Blinking eyes | 0 (0) | 1 (6) |
| Earache | 0 (0) | 1 (6) |
| Nasal discomfort | 0 (0) | 1 (6) |
| Gastrointestinal | ||
| Loose stool | 1 (7) | 0 (0) |
| Constipation | 1 (7) | 0 (0) |
| Stomach discomfort | 0 (0) | 1 (6) |
| Dermatological | ||
| Skin cut | 0 (0) | 2 (11) |
Fisher’s Exact Test was used to test for differences in adverse events between OXT-treated and placebo-treated individuals. No significant effects were discerned. Adverse events are reported as counts and percentages. HEENT, head, ears, eyes, nose, throat.